News
-
-
COMMUNIQUÉ DE PRESSE
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
Moderna Inc. and Cenra Healthcare enter joint agreement to co-promote mRNA respiratory vaccine portfolio in Taiwan, enhancing public health initiatives. Details undisclosed -
-
-
COMMUNIQUÉ DE PRESSE
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
Moderna initiates Phase 3 trial for mRNA-1403, an investigational norovirus vaccine, aiming to prevent infection from norovirus. Global recruitment has started -
-
-
COMMUNIQUÉ DE PRESSE
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Moderna's SPIKEVAX® KP.2 variant COVID-19 vaccine authorized in Canada for 2024-2025 season to protect against COVID-19 strains. Delivery to begin promptly for vaccination campaigns -
COMMUNIQUÉ DE PRESSE
Moderna reçoit l'approbation de Santé Canada pour le vaccin COVID-19 mis à jour ciblant le variant KP.2 du SRAS-COV-2 pour les personnes âgées de six mois et plus
Moderna Inc. obtient l'autorisation de Santé Canada pour son vaccin SPIKEVAX® mis à jour contre la COVID-19 pour le variant KP.2, renforçant la protection pendant les saisons automne-hiver 2024-2025 -
